ClinicalTrials.gg
Not yet recruitingNCT07844187Updated Sep 28, 2026

TQB2922 Injection Given Under the Skin With Chemotherapy as Initial Treatment for Colorectal Cancer That Has Spread

A Phase 1/2 interventional study of TQB2922 injection (subcutaneous administration) and Oxaliplatin in Colorectal Neoplasms, sponsored by Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.. Not yet recruiting at 16 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 1/2, Interventional, and Treatment

Updated Sep 28, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Colorectal Neoplasms by Sino Biopharmaceutical Limited — 6 open to participants now, 7 under way, 2 of them phase 3. Colorectal Neoplasms · Sino Biopharmaceutical Limited.

Planned enrollment
10th of 13
64 · median 72
Started
2026
with 2 others
Phase 1/2
4 of 13
3 open now
Registered
13th of 13
by date

Among the 13 studies in Colorectal Neoplasms by Sino Biopharmaceutical Limited, this one is the 10th largest by planned enrollment, is one of 3 that started in 2026, is one of 4 in phase 1/2, and was the 13th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

6 of the 13 studies in Colorectal Neoplasms by Sino Biopharmaceutical Limited are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Colorectal Neoplasms by Sino Biopharmaceutical Limited, or all of them as a file.
02

Study summary

This study will assess the safety and anticancer activity of TQB2922 injection given under the skin together with chemotherapy in adults with colorectal cancer that has spread, cannot be removed by surgery, and has no RAS or BRAF mutations. Participants have not received systemic treatment for advanced colorectal cancer, apart from the prior adjuvant treatment allowed by the protocol. TQB2922 is designed to block two proteins involved in cancer growth. The study tests whether adding TQB2922 to chemotherapy can improve tumor response with tolerable side effects. An initial safety stage will help select doses for further study. In the next stage, participants will be randomly assigned in a 2:1 ratio to two TQB2922 dose groups, each receiving mFOLFOX6 chemotherapy (oxaliplatin, calcium folinate, and fluorouracil). The planned TQB2922 doses are 2000 mg and 1600 mg, subject to the initial safety findings. Participants and doctors will know the treatment given. After 6 to 8 treatment cycles, maintenance treatment consists of TQB2922 and fluorouracil, with protocol-specified exceptions. Each participant may remain in the study for up to 24 months.

03

Conditions studied

  • Colorectal Neoplasms
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Voluntary participation with written and good compliance.
  • Age 18 to 75 years, inclusive, at informed consent.
  • (ECOG) performance status of 0 or 1.
  • greater than 12 weeks.
  • or cytologically confirmed unresectable colorectal cancer, staged according to the Union for International Cancer Control/American Joint Committee on Cancer (UICC/AJCC) TNM classification, 8th edition (2017).
  • RAS/BRAF wild-type status confirmed in tumor tissue.
  • At least one according to (RECIST) version 1.1.
  • Adequate laboratory results: >=90 g/L; >=1.5 x 10\^9/L; >=100 x 10\^9/L; total \<=1.5 times the (ULN); and aspartate aminotransferase \<=2.5 x ULN, or \<=5 x ULN with liver metastases; >=60 mL/min calculated using the modified Cockcroft-Gault formula; urine protein \<=1+, or, if >=2+, 24-hour urine protein \<1 g measured within 7 days; , activated partial thromboplastin time, and international normalized ratio \<=1.5 x ULN in participants not receiving anticoagulation; thyroid-stimulating hormone \<=ULN, or, if abnormal, normal triiodothyronine and thyroxine (or their free fractions).
  • Women of must have a negative serum or urine pregnancy test within 7 days before enrollment. Participants of must agree to effective during the study and for 6 months after study completion, following protocol section 5.4.4

Exclusion criteria

Exclusion Criteria:

  • Known high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR).
  • Other within 3 years before the first dose or a concurrent malignancy. Protocol-permitted exceptions include other malignancies treated by surgery alone with 5 consecutive years of disease-free survival, and cured cervical carcinoma in situ, nonmelanoma skin cancer, or superficial bladder tumors (Ta, Tis, or T1).
  • Disease affecting intravenous administration or venous blood collection, or factors affecting oral medication, such as inability to swallow, chronic diarrhea, or intestinal obstruction.
  • Toxicities from prior treatment not recovered to grade \<=1 by the National Cancer Institute (NCI CTCAE), version 6.0. Exceptions include grade 2 alopecia, peripheral neurotoxicity, or anemia; asymptomatic laboratory abnormalities without clinical significance; stable hypothyroidism on hormone replacement; and other toxicities judged not to pose a safety risk.
  • Major surgery or significant traumatic injury within 4 weeks before the first dose, expected major surgery during the study (except protocol-permitted surgery), or a persistently unhealed wound or fracture.
  • Poorly controlled active viral hepatitis. surface antigen-positive participants may be screened if hepatitis B virus (HBV) DNA is \<2000 IU/mL (or 1 x 10\^4 copies/mL), or if at least 1 week of anti-HBV treatment before study start has reduced viral load at least 10-fold, and they agree to anti-HBV treatment throughout the study. Participants positive for virus (HCV) antibody or HCV RNA may be screened if judged stable by the investigator, or if receiving antiviral treatment at enrollment and continuing approved antiviral treatment during the study.
  • History of noninfectious pneumonitis/interstitial lung disease requiring , or current noninfectious pneumonitis/interstitial lung disease; or hospitalization or therapeutic antibiotics for active infection within 4 weeks before study treatment, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
  • History of psychiatric drug abuse that cannot be discontinued, or a psychiatric disorder.
  • Planned or previous bone marrow transplantation or solid organ transplantation.
  • History of hepatic encephalopathy.
  • Significant cardiovascular disease, including any of the following: (NYHA) class II or higher cardiac dysfunction or \<50%; ventricular arrhythmia or arrhythmia requiring continuous antiarrhythmic therapy; unstable angina; myocardial infarction within 12 months; Fridericia- interval >450 ms in men or >470 ms in women (an abnormal value may be assessed by the mean of 3 measurements at least 2 minutes apart); personal or family history of congenital long QT syndrome; arterial or venous thrombosis within 6 months before the first dose; systolic blood pressure >=150 mmHg and/or diastolic blood pressure >=90 mmHg despite standard treatment, or prior hypertensive encephalopathy/crisis; clinically significant tumor bleeding/perforation or grade >=3 bleeding within 1 month before treatment; bleeding/coagulation disease while receiving warfarin, aspirin, or other antiplatelet agents (except maintenance aspirin \<=100 mg/day or clopidogrel \<=75 mg/day); or other bleeding signs/history judged unsuitable by the investigator.
  • Poorly controlled diabetes with fasting blood glucose >10 mmol/L.
  • Active or uncontrolled serious infection of CTCAE grade >=2.
  • Renal failure requiring hemodialysis or peritoneal dialysis.
  • History of immunodeficiency, including (HIV) positivity or another acquired or congenital immunodeficiency.
  • Use of or systemic or absorbable topical steroids for immunosuppression, with continued use required within 7 days before the first dose; except prednisone \<10 mg/day or an equivalent glucocorticoid dose.
  • Epilepsy requiring treatment.
  • Any of the following cancer-related conditions or treatments: chemotherapy/immunotherapy within 3 weeks, radiotherapy/small-molecule targeted therapy within 2 weeks, or treatment within 5 drug half-lives before the first dose (the shortest interval, as stated in the protocol); Chinese patent medicines with a National Medical Products Administration (NMPA)-approved anticancer indication within 2 weeks before the first dose; uncontrolled, symptomatic, or repeatedly drained pleural, peritoneal, or pericardial effusions (small, asymptomatic imaging-only effusions without drainage or treatment in the preceding 2 weeks are allowed); known central nervous system and/or carcinomatous meningitis (except asymptomatic cases, or treated stable cases without imaging evidence of new/enlarging for at least 2 weeks after brain-metastasis treatment and off steroids/anticonvulsants for at least 14 days before study treatment); or severe bone damage/spinal cord compression from bone metastases, including weight-bearing pathological fractures within 6 months or anticipated soon, or poorly controlled severe bone pain.
  • Known allergy to of the study drug.
  • Prior antiangiogenic or anti-epidermal growth factor receptor (EGFR) targeted treatment, including bevacizumab, cetuximab, panitumumab, or aflibercept.
  • Prior systemic treatment for advanced colorectal cancer. treatment is permitted if completed >12 months before study start for oxaliplatin-containing chemotherapy, or >6 months for chemotherapy without oxaliplatin, measured from the last chemotherapy dose.
  • Receipt of another anticancer drug within 4 weeks before the first dose.
  • Any other condition that, in the investigator's judgment, seriously compromises safety or the ability to complete the study.
Terms in these criteria, in plain language(34)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
64 participants (estimated)

Study arms

  • Experimental
    Phase Ib safety run-in: TQB2922 injection + mFOLFOX6

    Nonrandomized safety run-in. TQB2922 starts at 2000 mg; separate 1600 mg and 1200 mg cohorts may be enrolled sequentially if dose reduction is needed for intolerance. TQB2922 is given subcutaneously on days 1, 8, 15, and 22 of cycle 1 and on days 1 and 15 of later 28-day cycles, with oxaliplatin, calcium folinate, and fluorouracil (mFOLFOX6) every 2 weeks. After 6 to 8 cycles, maintenance comprises TQB2922 plus fluorouracil, subject to protocol-permitted exceptions and stopping rules.

    Drug: TQB2922 injection (subcutaneous administration) · Drug: Oxaliplatin · Drug: Calcium folinate (leucovorin calcium) · Drug: Fluorouracil

  • Experimental
    Phase II 2000 mg group: TQB2922 injection + mFOLFOX6

    Participants in phase II are randomized 2:1 to the 2000 mg and 1600 mg groups. This group receives TQB2922 2000 mg; final dose selection depends on phase Ib safety and tolerability. TQB2922 is given subcutaneously on days 1, 8, 15, and 22 of cycle 1 and on days 1 and 15 of later 28-day cycles, with oxaliplatin, calcium folinate, and fluorouracil (mFOLFOX6) every 2 weeks. After 6 to 8 cycles, maintenance comprises TQB2922 plus fluorouracil, subject to protocol-permitted exceptions and stopping rules.

    Drug: TQB2922 injection (subcutaneous administration) · Drug: Oxaliplatin · Drug: Calcium folinate (leucovorin calcium) · Drug: Fluorouracil

  • Experimental
    Phase II 1600 mg group: TQB2922 injection + mFOLFOX6

    Participants in phase II are randomized 2:1 to the 2000 mg and 1600 mg groups. This group receives TQB2922 1600 mg; final dose selection depends on phase Ib safety and tolerability. TQB2922 is given subcutaneously on days 1, 8, 15, and 22 of cycle 1 and on days 1 and 15 of later 28-day cycles, with oxaliplatin, calcium folinate, and fluorouracil (mFOLFOX6) every 2 weeks. After 6 to 8 cycles, maintenance comprises TQB2922 plus fluorouracil, subject to protocol-permitted exceptions and stopping rules.

    Drug: TQB2922 injection (subcutaneous administration) · Drug: Oxaliplatin · Drug: Calcium folinate (leucovorin calcium) · Drug: Fluorouracil

Interventions

  • TQB2922 is an investigational bispecific antibody targeting epidermal growth factor receptor and c-Met. Administered subcutaneously at the assigned dose: weekly in cycle 1, then every 2 weeks in 28-day cycles. Phase Ib starts at 2000 mg with possible cohort dose reductions to 1600 mg and 1200 mg. Phase II planned doses are 2000 mg and 1600 mg, subject to phase Ib findings. Continued with fluorouracil during maintenance.

  • Platinum-based antineoplastic component of mFOLFOX6. Oxaliplatin 85 mg/m\^2 by intravenous infusion every 2 weeks during the 6-to-8-cycle treatment phase. Used in all study arms; not listed in the protocol maintenance regimen.

  • Folate component of mFOLFOX6. Calcium folinate 400 mg/m\^2 by intravenous infusion every 2 weeks during the 6-to-8-cycle treatment phase. Used in all study arms; not listed in protocol section 6.2.1 for maintenance.

  • Antimetabolite component of mFOLFOX6. Fluorouracil 400 mg/m\^2 by intravenous bolus followed by 2400 mg/m\^2 by continuous intravenous infusion over 46 hours, repeated every 2 weeks. Used in all study arms during treatment and continued with TQB2922 in maintenance.

06

What researchers measure

Primary outcomes

  1. Recommended phase II dose (RP2D), phase Ib

    Dose(s) of TQB2922 for combination with mFOLFOX6 selected jointly by the investigator and sponsor after assessment of safety, tolerability, pharmacokinetics, and preliminary activity in the phase Ib safety run-in.

    Time frame: During the Phase Ib safety run-in period, approximately 28 days.

  2. Incidence and severity of adverse events, phase Ib

    Percentage of participants with adverse events (AEs), with severity graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 6.0. Predose events are handled as specified in protocol section 8.4.1.

    Time frame: From informed consent to 30 days after the last dose or start of new anticancer therapy, whichever occurs first; study participation up to 24 months.

  3. Incidence and severity of serious adverse events, phase Ib

    Percentage of participants with serious adverse events (SAEs), with severity graded using NCI CTCAE version 6.0. Seriousness is assessed using the criteria in protocol section 8.4.5.

    Time frame: From informed consent to 30 days after the last dose or start of new anticancer therapy, whichever occurs first; study participation up to 24 months.

  4. Incidence and severity of laboratory abnormalities, phase Ib

    Percentage of participants with laboratory abnormalities and their severity, graded using NCI CTCAE version 6.0 where applicable. Laboratory assessments include hematology, biochemistry, coagulation, urinalysis, and thyroid function.

    Time frame: From informed consent to 30 days after the last dose or start of new anticancer therapy, whichever occurs first; study participation up to 24 months.

  5. Objective response rate (ORR), phase II

    Percentage of participants with a best overall response of complete response (CR) or partial response (PR), assessed by the investigator using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.

    Time frame: From baseline, every 6 weeks (+/-7 days) through week 48 and every 12 weeks (+/-7 days) thereafter; up to 24 months.

  6. Disease control rate (DCR), phase II

    Percentage of participants with a best overall response of CR, PR, or stable disease (SD), assessed by the investigator using RECIST version 1.1.

    Time frame: From baseline, every 6 weeks (+/-7 days) through week 48 and every 12 weeks (+/-7 days) thereafter; up to 24 months.

  7. Progression-free survival (PFS), phase II

    Time from randomization to investigator-assessed disease progression according to RECIST version 1.1 or death from any cause, whichever occurs first.

    Time frame: From baseline, every 6 weeks (+/-7 days) through week 48 and every 12 weeks (+/-7 days) thereafter; up to 24 months.

  8. Duration of response (DOR), phase II

    Among responders, time from the first documented CR or PR to investigator-assessed disease progression according to RECIST version 1.1 or death from any cause, whichever occurs first.

    Time frame: From baseline, every 6 weeks (+/-7 days) through week 48 and every 12 weeks (+/-7 days) thereafter; up to 24 months.

Secondary outcomes

  1. Peak concentration (Cmax), phase Ib

    Maximum observed concentration of TQB2922. Estimated by noncompartmental analysis in participants undergoing intensive pharmacokinetic (PK) sampling. C denotes cycle and D denotes day.

    Time frame: Within 2 hours before dosing on specified days of Cycles 1, 2, 4 and 8; through 72 hours after dosing on Day 1 of Cycle 1 and through 168 hours after dosing on Day 1 of Cycle 4 (28-day cycles; sampling windows specified in the description).

  2. Area under the concentration-time curve from time zero to the last quantifiable concentration (AUC0-t), phase Ib

    Area under the TQB2922 concentration-time curve from time zero to the last quantifiable concentration. Estimated by noncompartmental analysis in participants undergoing intensive pharmacokinetic (PK) sampling. C denotes cycle and D denotes day.

    Time frame: Within 2 hours before dosing on specified days of Cycles 1, 2, 4 and 8; through 72 hours after dosing on Day 1 of Cycle 1 and through 168 hours after dosing on Day 1 of Cycle 4 (28-day cycles; sampling windows specified in the description).

  3. Time to peak concentration (Tmax), phase Ib

    Time to the maximum observed TQB2922 concentration. Estimated by noncompartmental analysis in participants undergoing intensive pharmacokinetic (PK) sampling. C denotes cycle and D denotes day.

    Time frame: Within 2 hours before dosing on specified days of Cycles 1, 2, 4 and 8; through 72 hours after dosing on Day 1 of Cycle 1 and through 168 hours after dosing on Day 1 of Cycle 4 (28-day cycles; sampling windows specified in the description).

  4. Terminal elimination rate constant (lambda z), phase Ib

    Terminal elimination rate constant estimated from the TQB2922 concentration-time profile. Estimated by noncompartmental analysis in participants undergoing intensive pharmacokinetic (PK) sampling. C denotes cycle and D denotes day.

    Time frame: Within 2 hours before dosing on specified days of Cycles 1, 2, 4 and 8; through 72 hours after dosing on Day 1 of Cycle 1 and through 168 hours after dosing on Day 1 of Cycle 4 (28-day cycles; sampling windows specified in the description).

  5. Elimination half-life (t1/2), phase Ib

    Time required for the TQB2922 concentration to decrease by half in the terminal elimination phase. Estimated by noncompartmental analysis in participants undergoing intensive pharmacokinetic (PK) sampling. C denotes cycle and D denotes day.

    Time frame: Within 2 hours before dosing on specified days of Cycles 1, 2, 4 and 8; through 72 hours after dosing on Day 1 of Cycle 1 and through 168 hours after dosing on Day 1 of Cycle 4 (28-day cycles; sampling windows specified in the description).

  6. Apparent clearance (CL/F), phase Ib

    Apparent clearance of TQB2922 following subcutaneous administration. F denotes bioavailability. Estimated by noncompartmental analysis in participants undergoing intensive pharmacokinetic (PK) sampling. C denotes cycle and D denotes day.

    Time frame: Within 2 hours before dosing on specified days of Cycles 1, 2, 4 and 8; through 72 hours after dosing on Day 1 of Cycle 1 and through 168 hours after dosing on Day 1 of Cycle 4 (28-day cycles; sampling windows specified in the description).

  7. Apparent terminal volume of distribution (Vz/F), phase Ib

    Apparent volume of distribution of TQB2922 during the terminal phase following subcutaneous administration. Estimated by noncompartmental analysis in participants undergoing intensive pharmacokinetic (PK) sampling. C denotes cycle and D denotes day.

    Time frame: Within 2 hours before dosing on specified days of Cycles 1, 2, 4 and 8; through 72 hours after dosing on Day 1 of Cycle 1 and through 168 hours after dosing on Day 1 of Cycle 4 (28-day cycles; sampling windows specified in the description).

  8. Extrapolated percentage of AUC0-infinity (%AUCextrap), phase Ib

    Percentage of the total TQB2922 AUC extrapolated from the last quantifiable concentration to infinity. Estimated by noncompartmental analysis in participants undergoing intensive pharmacokinetic (PK) sampling. C denotes cycle and D denotes day.

    Time frame: Within 2 hours before dosing on specified days of Cycles 1, 2, 4 and 8; through 72 hours after dosing on Day 1 of Cycle 1 and through 168 hours after dosing on Day 1 of Cycle 4 (28-day cycles; sampling windows specified in the description).

  9. Objective response rate (ORR), phase Ib

    Percentage of participants with a best overall response of complete response (CR) or partial response (PR), assessed by the investigator using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.

    Time frame: From baseline, every 6 weeks (+/-7 days) through week 48 and every 12 weeks (+/-7 days) thereafter; up to 24 months.

  10. Disease control rate (DCR), phase Ib

    Percentage of participants with a best overall response of CR, PR, or stable disease (SD), assessed by the investigator using RECIST version 1.1.

    Time frame: From baseline, every 6 weeks (+/-7 days) through week 48 and every 12 weeks (+/-7 days) thereafter; up to 24 months.

  11. Progression-free survival (PFS), phase Ib

    Time from first dose to investigator-assessed disease progression according to RECIST version 1.1 or death from any cause, whichever occurs first.

    Time frame: From baseline, every 6 weeks (+/-7 days) through week 48 and every 12 weeks (+/-7 days) thereafter; up to 24 months.

  12. Duration of response (DOR), phase Ib

    Among responders, time from the first documented CR or PR to investigator-assessed disease progression according to RECIST version 1.1 or death from any cause, whichever occurs first.

    Time frame: From baseline, every 6 weeks (+/-7 days) through week 48 and every 12 weeks (+/-7 days) thereafter; up to 24 months.

  13. Incidence of anti-drug antibodies (ADA), phase Ib

    Percentage of participants with anti-TQB2922 antibodies detected by a validated assay. ADA-positive samples undergo neutralizing-antibody testing. C denotes cycle and D denotes day.

    Time frame: Within 2 hours before dosing on Day 1 of Cycles 1, 2, 4 and 8; at end of treatment; and 90 days (+/-7 days) after the last dose. Additional samples for protocol-specified reactions.

  14. Incidence and severity of adverse events, phase II

    Percentage of participants with adverse events (AEs), with severity graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 6.0. Predose events are handled as specified in protocol section 8.4.1.

    Time frame: From informed consent to 30 days after the last dose or start of new anticancer therapy, whichever occurs first; study participation up to 24 months.

  15. Incidence and severity of serious adverse events, phase II

    Percentage of participants with serious adverse events (SAEs), with severity graded using NCI CTCAE version 6.0. Seriousness is assessed using the criteria in protocol section 8.4.5.

    Time frame: From informed consent to 30 days after the last dose or start of new anticancer therapy, whichever occurs first; study participation up to 24 months.

  16. Incidence and severity of laboratory abnormalities, phase II

    Percentage of participants with laboratory abnormalities and their severity, graded using NCI CTCAE version 6.0 where applicable. Laboratory assessments include hematology, biochemistry, coagulation, urinalysis, and thyroid function.

    Time frame: From informed consent to 30 days after the last dose or start of new anticancer therapy, whichever occurs first; study participation up to 24 months.

07

Study locations

16 sites
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Aug 2027, 10 months later.

Of 158 industry-sponsored phase 1/2 interventional studies under Colorectal Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 82. This study's planned 10 months is below that.

Counting every sponsor, half of 260 studies reached it within 59 months; a quarter within 36 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2026
First posted
Sep 28, 2026
StartEst.
Oct 20, 2026
Primary completionEst.
Aug 31, 2027
CompletionEst.
Mar 31, 2028
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07844187
Responsible party
Sponsor
First posted
Sep 28, 2026
Start date
Oct 20, 2026 (estimated)
Primary completion
Aug 31, 2027 (estimated)
Completion
Mar 31, 2028 (estimated)
Last update
Sep 28, 2026

Study contacts

Yanhong Gu, Doctor of Medicine
Contact
guyanhong@jsph.org.cn
+86 13813908678

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TQB2922

Start the discussion